Season 2, Episode 20

In this week’s episode, we will examine the prognostic significance of co-mutations in IDH-mutated AML, explore an alternative method of warfarin monitoring, and finally, consider the role of tumor suppressor TP53 in determining response to venetoclax and related agents.

Released May 20, 2021

The articles highlighted in this episode are listed below:

• Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study

  Authors: Matthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, Jean-Pierre Marolleau, Thorsten Braun, Lionel Adès, Sylvain Chantepie, Emilie Lemasle, Céline Berthon, Jean-Valère Malfuson, Cécile Pautas, Juliette Lambert, Nicolas Boissel, Karine Celli-Lebras, Denis Caillot, Pascal Turlure, Norbert Vey, Arnaud Pigneux, Christian Recher, Christine Terré, Claude Gardin, Raphaël Itzykson, Claude Preudhomme, Hervé Dombret, Stéphane de Botton

• What can Heraclitus tell us about AML?

  Author: Arnold Ganser

• Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study

  Authors: Alma R. Oskarsdottir, Brynja R. Gudmundsdottir, Hulda M. Jensdottir, Bjorn Flygenring, Ragnar Palsson, Pall T. Onundarson

• A better way to monitor warfarin therapy?

  Author: Daniel M. Witt

• Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

  Authors: Rachel Thijssen, Sarah T. Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X. Shi, Michael A. Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S. Anstee, Boris Reljić, Sarah S. Gabriel, Tirta M. Djajawi, Chris D. Riffkin, Brandon J. Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, Giovanna Pomilio, Claudia Bruedigam, Axel Kallies, David A. Stroud, Ashish Bajel, Ruth M. Kluck, Steven W. Lane, Marie Schoumacher, Sébastien Banquet, Ian J. Majewski, Andreas Strasser, Andrew W. Roberts, David C. S. Huang, Fiona C. Brown, Gemma L. Kelly, Andrew H. Wei

• Targeting MCL-1 and BCL-2: a 1-2 punch

  Authors: Jennifer R. Brown